Evidence map›Paper›PMID 35435593›Full record

ArticleEJNMMI research2022

Larger

Ziren Kong, Zhu Li, Junyi Chen, Wenbin Ma, Yu Wang, Zhi Yang, Zhibo Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. CD98 Light Chain LAT1 Tracers in PET-CT Diagnosis of Cancer Patients.Anti-cancer agents in medicinal chemistry · 2026
    Review
  2. Review
  3. Article
  4. A bis-boron boramino acid PET tracer for brain tumor diagnosis.European journal of nuclear medicine and molecular imaging · 2024
    Article
  5. Preclinical and Clinical Use of Indigenously DevelopedACS pharmacology & translational science · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ziren Kong *Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhu Li *Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Junyi Chen *Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Wenbin MaDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yu WangDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ywang@pumch.cn.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China. pekyz@163.com.
Zhibo LiuBeijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China. zbliu@pku.edu.cn.ORCID http://orcid.org/0000-0002-5587-4165
Peking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Beijing Municipal Commission of Education 3500-12020123Beijing Municipal Natural Science Foundation 19JCZDJC64200(Z)Beijing Municipal Natural Science Foundation 7202150Beijing Municipal Natural Science Foundation Z200018Ministry of Science and Technology of the People's Republic of China 2017YFA0506300Ministry of Science and Technology of the People's Republic of China 2021YFA1601400National Natural Science Foundation of China 21778003National Natural Science Foundation of China U1867209Peking University LGZNQN202004Tsinghua University 2019ZLH101
6 · The paper itself

Abstract

backgroundTo investigate the relationship between

methodsA total of 16 diffuse gliomas and 7 circumscribed brain tumors were included, and two types of three-dimensional regions of interest (ROIs), namely, MRI-based ROI (ROI

resultsThe ROI

conclusionFBY uptake beyond contrast enhancement is more significant in diffuse tumors than in circumscribed tumors, which may aid the delineation of active tumor areas and facilitate boron neutron capture therapy.

Indexed as

Boron neutron capture therapyBrain tumorDiffuse gliomaFluoroboronotyrosineMetastasisPETVolume comparison

Identifiers

PMID35435593
PMCPMC9016106
OpenAlexW4224032425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.